KRTAP21-3

Across TCGA pan-cancer cohorts, KRTAP21-3 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated KRTAP21-3 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher KRTAP21-3 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated KRTAP21-3 expression acts as an unfavorable survival marker, although some lineages such as ESCA show a favorable association.

LIHC, BLCA, and COAD are the cancer types where KRTAP21-3 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.043	0.527	<.001	60	view →
BLCA	DFS	Tertile	All	0.238	0.629	.004	54	view →
COAD	OS	Tertile	IV	0.039	0.660	<.001	36	view →
READ	DFS	Tertile	All	0.178	0.808	<.001	36	view →
LGG	OS	Tertile	All	0.194	0.830	<.001	24	view →
ESCA	DFS	Tertile	All	0.565	0.271	.011	15	view →
KIRC	OS	Tertile	All	0.420	0.648	.016	9	view →
STAD	DFS	Tertile	II,III,IV	0.531	0.705	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

KRTAP21-3–LIHC (DFS)

Open the LIHC breakdown →